Last updated: November 16, 2023
Sponsor: Sofwave Medical LTD
Overall Status: Completed
Phase
N/A
Condition
N/ATreatment
Sofwave
Clinical Study ID
NCT05882721
Sofwave19
Ages 18-60 Female Accepts Healthy Volunteers
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
- Healthy female subjects > 18 years of age and < 60 years of age
- Not pregnant or lactating and must be either post-menopausal, surgically sterilized,or using a medically acceptable form of birth control at least 3 months prior toenrollment (i.e., oral contraceptives, contraceptive implant, barrier methods withspermicide) or abstinence.
- Have visible cellulite in the upper thigh and/or buttock areas.
- Seeking treatment of cellulite in the upper thigh and/or buttock areas.
- Stable weight nominally ±5% for at least past 6 months
- Subject agrees to maintain her weight (i.e., within 5% of total body weight) by notmaking any major changes in their diet or exercise routine during the study course.
- Subject did not undergo invasive or energy-based cellulite treatments (liposuction,subcision, RF, laser, ESWT, etc.) for the prior 12 months.
- Subject did not use topical based cellulite treatments for prior 6 months and will notuse during the trial (except for the study related procedures)
- Subject agrees not to undergo any other cellulite treatments for a period of 3 monthsfollowing SofWave treatment
- Willing to have photographs of the treated areas. Agree for de-identified study imagesto be used in evaluations, publications, and presentations.
- Able and willing to comply with all visits, treatments and evaluations schedules andrequirements.
- Able to understand and provide written Informed Consent.
Exclusion
Exclusion Criteria:
- Pregnant or planning to become pregnant during the duration of the study, having givenbirth less than 3 months ago, and/or breast feeding
- Currently heavy smoker or has history of heavy smoking (25 cigarettes per day or more)in past 10 years
- BMI>=30kg/m2
- Non-stable weight nominally ±5% for at least past 6 months
- Currently taking or has taken diet pills or weight control supplements within the pastmonth
- History of severe migraine tendency
- History of Epileptic seizures
- History of chronic drug or alcohol abuse
- History of coagulopathy(ies) and/or on anticoagulant medication
- History of bleeding disorder or is taking any medication that in the investigator'sopinion may increase the subject's risk of bruising
- Medical disorder that would hinder the wound healing or immune response (such as blooddisorder, inflammatory disease, etc.)
- Active implanted device such as a pacemaker, defibrillator, cochlear implants,nerve/brain stimulators or drug delivery system
- Known allergy to lidocaine or epinephrine or antibiotics
- Active malignancy or history of malignancy in the past 5 years
- Suffering from significant concurrent illness, such as cardiac disorders, diabetes (type I or II), lupus, porphyria, or pertinent neurological disorders (i.e., anydisease state that in the opinion of the investigator may interfere with theanesthesia, treatment, or healing process)
- History of immunosuppression/immune deficiency disorders (including HIV infection orAIDS) or currently using immunosuppressive medications
- Suffering from hormonal imbalance, whether related to thyroid, pituitary, or androgen
- History of significant lymphatic drainage problems
- History of epidermal or dermal disorders (particularly involving collagen ormicrovascularity), including collagen vascular disease or vasculitic disorders.
- Skin disorders (skin infections or rashes, extensive scarring, psoriasis, etc.) in thetreatment area.
- Severe solar elastosis on the intended to treat area.
- Significant scarring, atrophic scars in the area to be treated, or has a history ofatrophic scars or keloids or prone to bruising
- Tattoo or former tattoo at or near treatment area
- Presence of an implant (metal or plastic) in or adjacent to area of intended treatment (vascular stent, or implants in the hips, knees, etc)
- Inability to understand the protocol or to give informed consent
- On-going use of psychiatric medication
- Unable or unwilling to comply with the study requirements and procedures
- Unwilling to have research photos taken of treatment areas
- Currently enrolled in a clinical study of any other unapproved investigational drug ordevice
- Any other condition that would, in the professional opinion of the investigator,potentially affect the subject's response or the integrity of the data or would posean unacceptable risk to the subject
Study Design
Total Participants: 60
Treatment Group(s): 1
Primary Treatment: Sofwave
Phase:
Study Start date:
February 20, 2023
Estimated Completion Date:
November 15, 2023
Study Description
Connect with a study center
Laser & Skin Surgery Center of Northern California
Sacramento, California 95816
United StatesSite Not Available
Schweiger Dermatology GP Research
Hackensack, New Jersey 07601
United StatesSite Not Available
UnionDerm
New York, New York 10003
United StatesSite Not Available
Main Line Center for Laser Surgery
Ardmore, Pennsylvania 19003
United StatesSite Not Available
Tennessee Clinical Research Center
Nashville, Tennessee 37215
United StatesSite Not Available
Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.